Medicines for the management of overweight and obesity: A systematic review with network meta-analysis
Authors:
- Gabriela Masiero MarconGMGabriela Masiero Marcon
- Jhonatan Mendes PaivaJPJhonatan Mendes Paiva
- Mariana Delariva SakiyamaMSMariana Delariva Sakiyama
- Fernanda Stumpf ToninFTFernanda Stumpf Tonin
- Fernando Fernandez-LlimosFFFernando Fernandez-Llimos
- Suzane VirtuosoSVSuzane Virtuoso
- Andreia Cristina Conegero SanchesASAndreia Cristina Conegero Sanches
Open Access
- 1 January 2025
- journal article
- review article
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Pharmaceutical Sciences
- Vol. 61, e24177
Abstract
To synthesize the evidence about pharmacologic treatment of obesity and overweight and to define the options with the best risk-benefit using the stochastic analysis of multicriteria acceptability (SMAA). The analysis addresses a systematic review (PROSPERO CRD42023423308) whose research was realized in PubMed, Scopus, and Web of Science. Randomized controlled trials were included, which verified the effects of sibutramine, orlistat, liraglutide, and semaglutide in patients with IMC ≥ 26 Kg/ m². The risk of bias analysis was performed with RoB 2.0 and the outcomes evaluated were weight loss and serious adverse events. A total of 102 studies with 45.047 participants were included. The network meta-analysis revealed that all the treatments were significantly more effective than the placebo in weight reduction. The use of semaglutide (especially 0.4 mg/day) was associated with a bigger weight loss in comparison to all the other treatments (p<0.05) and the analysis of SMAA showed a risk-benefit of 95%. Besides that, we suggest re-evaluating of sibutramine 10mg/day as a therapeutic option for patients without hypertension or cardiovascular diseases, and we demonstrate the modest weight loss promoted by orlistat 120mg, sibutramine 5mg, and liraglutide 1,8mg and advise against its use, once the benefits do not outweigh the risks.Keywords
This publication has 37 references indexed in Scilit:
- Pharmaceutical Therapies for the Treatment of Obesity: A Network Meta-analysisClinical Therapeutics, 2023
- Comparative efficacy and safety of systemic antifungal agents for candidemia: a systematic review with network meta-analysis and multicriteria acceptability analysesInternational Journal of Antimicrobial Agents, 2022
- Mental Health and Obesity During the COVID-19 PandemicCurrent Obesity Reports, 2022
- Efficacy and safety of oral phosphodiesterase 5 inhibitors for erectile dysfunction: a network meta-analysis and multicriteria decision analysisWorld Journal of Urology, 2020
- Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse EventsJAMA, 2016
- Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1Value in Health, 2011
- Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2Value in Health, 2011
- A stochastic multicriteria model for evidence‐based decision making in drug benefit‐risk analysisStatistics in Medicine, 2011
- Combination of direct and indirect evidence in mixed treatment comparisonsStatistics in Medicine, 2004
- The Efficacy and Safety of Sibutramine for Weight LossArchives of internal medicine (1960), 2004